U.S. License Holder:
Astrazeneca AB
Date of License:
September-13-2018
Last Update:
Dec-15-2024
FDA-Approved Indications
LUMOXITI (moxetumomab pasudotox-tdfk) is a CD22-directed cytotoxin indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA).